Vaxcyte (PCVX) Income from Continuing Operations (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Income from Continuing Operations data on file, last reported at 322947000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 113.95% year-over-year to 322947000.0 in Q1 2026; TTM through Mar 2026 was 1348394000.0, a 160.47% decrease from a year earlier, with the FY2025 full-year figure at 1449270000.0, down 60.03% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 322947000.0, up from 378183000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for PCVX reached as high as 79940000.0 in Q4 2022 and fell as low as 455931000.0 in Q1 2024.
• Historically, Income from Continuing Operations has averaged 224236000.0 across 5 years, with a median of 179108000.0 in 2023.
• Across the five-year window, Income from Continuing Operations tumbled 380.33% in 2022 and soared 66.89% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 79940000.0 in 2022, then sank by 124.05% to 179108000.0 in 2023, then jumped by 34.51% to 117305000.0 in 2024, then sank by 222.39% to 378183000.0 in 2025, then grew by 14.61% to 322947000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 322947000.0 in Q1 2026, 378183000.0 in Q4 2025, and 331148000.0 in Q3 2025.